Cargando…
Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
Type 2 diabetes mellitus (T2DM) has become a worldwide health problem, and the rate of it is growing greatly in the People’s Republic of China every year. T2DM could cause macrovascular and microvascular complications that lead to an increase in arterial wall thickness, endothelial dysfunction, calc...
Autores principales: | Wang, Hongyu, Liu, Jinbo, Zhao, Hongwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322603/ https://www.ncbi.nlm.nih.gov/pubmed/25678772 http://dx.doi.org/10.2147/DDDT.S53048 |
Ejemplares similares
-
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013) -
Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015) -
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014) -
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
por: Kaku, Kohei, et al.
Publicado: (2019) -
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)